THE CORONAVIRUS VACCINE developed by Pfizer and BioNTech protects against the virus for at least six months and provides full protection from the variant first detected in South Africa, a version of the virus experts feared would evade vaccine protection.
https://digg.com/@watch-godzilla-vs-kong-2021-movie-online-full-free
https://digg.com/@watch-zack-snyder-s-justice-league-2021-online-full
https://digg.com/@watch-raya-and-the-last-dragon-2021-online-full-hd
https://digg.com/@hd-watch-nobody-2021-online-full-hd-free
https://digg.com/@watch-the-unholy-2021-online-full-hd-free
https://digg.com/@s1-e3-the-falcon-and-the-winter-soldier-s1-ep3-watch
https://www.open.edu/openlearn/profiles/zu13939
https://www.open.edu/openlearn/profiles/zu13968
http://www.shadowville.com/board/general-discussions/sfsdfsdfsdf
https://isbacktoday.substack.com/publish/post/34687268
The companies announced on Thursday more results from the ongoing phase three trial of their vaccine, revealing that recipients of the two-dose vaccine course are protected for at least six months after the second dose, which is longer than the best estimate of 90-day protection initially proposed.
Cartoons on the Coronavirus
View All 536 Images
The vaccine remains 91.3% effective against symptomatic COVID-19 measured seven days through six months after the second dose. While half a year is a modest timeline, the results are just the first look at how long protection from a COVID-19 vaccine lasts.
Recommended Videos
Powered by AnyClip
Pfizer says its vaccine is safe for kids age 12 to 15
628
Play Video
NOW PLAYINGPfizer says its vaccine is safe for kids age 12 to 15
Pfizer says its Covid-19 vaccine protects younger teens
Doctor answers questions about COVID-19 vaccine for kids
Pfizer says vaccine safe, effective on adolescents in trial
Moderna coronavirus vaccine 'adds another string to our bow'
However, the results do raise the question of whether people will need additional booster shots in the future for continued protection against the virus.
Additionally, the phase three results show that the vaccine is completely effective on the concerning variant that it is now the dominant strain in South Africa.
"The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccine's overall effectiveness," the companies said.
https://caribbeanfever.com/photo/albums/dsfsdfsdfsdfcvbcv
http://network-marketing.ning.com/profiles/blogs/dsfsdfsdfvvnvbn
https://www.onfeetnation.com/profiles/blogs/sdfsdfsdbnvbuiu
https://webhitlist.com/profiles/blogs/sdfsdfsdcnvnbv
http://recampus.ning.com/profiles/blogs/dsfsdfsdbnvbvnbn
http://millionairex3.ning.com/profiles/blogs/fdsfsdfvnvbnvbn
http://beterhbo.ning.com/profiles/blogs/dfsdfsdcvbvcnbvnvbnvs
Albert Bourla, chairman and CEO of Pfizer, said the "data confirm the favorable efficacy and safety profile of our vaccine and position us to submit a Biologics License Application to the U.S. FDA."
A BLA is an application for full approval. Pfizer's vaccine is currently approved in the U.S. for emergency use.
The vaccine also continues to be safe and well tolerated over the six-month period.